

also attend the meeting via webcast. Instructions for attending via webcast will be posted at least one week prior to the meeting at <https://www.hhs.gov/ohrp/sachrp-committee/meetings/index.html>.

FOR FURTHER INFORMATION CONTACT: Julia Gorey, J.D., Executive Director, SACHRP; U.S. Department of Health and Human Services, 1101 Wootton Parkway, Suite 200, Rockville, Maryland 20852; telephone: 240-453-8141; fax: 240-453-6909; email address: SACHRP@hhs.gov.

SUPPLEMENTARY INFORMATION: Under the authority of 42 U.S.C. 217a, section 222 of the Public Health Service Act, as amended, SACHRP was established to provide expert advice and recommendations to the Secretary of Health and Human Services, through the Assistant Secretary for Health, on issues and topics pertaining to or associated with the protection of human research subjects.

The SACHRP Advisory Subcommittee was established by in August 2024 and is charged with assessing and drafting recommendations for consideration by SACHRP pertaining to the language and interpretation of 45 CFR part 46, existing relevant HHS guidance documents and the development of new HHS guidance documents, and cultural, ethical, or international issues of concern which may impact HHS funded human subjects protections.

The SACHRP meeting will open to the public at 11:00 a.m., on Tuesday, October 22, 2024, followed by opening remarks from Julie Kaneshiro, currently Acting Director of OHRP. Ms Kaneshiro will introduce Dr. Molly Klote, newly appointed Director of OHRP. Dr. Douglas Diekema, SACHRP Chair, will make opening remarks. The meeting will begin with a discussion of the draft recommendation, Considerations for Uninformative Research. This will be followed by panel presentations and discussion of a new SACHRP topic on Equivalent Protections and Procedural Requirements in International Research. The day will adjourn at approximately 4:30 p.m.

Time will be allotted for public comment. SACHRP materials will be publicly posted at HHS-OASH-2024-0013. The public may submit written public comment in advance to SACHRP@hhs.gov no later than midnight October 18th, 2024, ET. Written comments will be shared with SACHRP members and may read aloud during the meeting. Comments which are read aloud are limited to three minutes each. Public comment must be

relevant to topics currently being addressed by the SACHRP.

Dated: September 26, 2024.

Julia G. Gorey.

Executive Director, SACHRP, Office for Human Research Protections.

[FR Doc. 2024-24147 Filed 10-17-24; 8:45 am]

BILLING CODE 4150-36-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

This will be a hybrid meeting held in-person and virtually and will be open to the public as indicated below. Given the capacity constraints of the venue, the public is strongly encouraged to attend virtually via NIH videocast. Interested individuals should pre-register at <https://cvent.me/vxOKqy> to attend this meeting. Individuals who need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocasting website (<http://videocast.nih.gov/>).

Name of Committee: Scientific Management Review Board.

Date: November 12, 2024.

Time: 11:15 a.m. to 5:30 p.m.

Agenda: Overview of NIH's mission, structure, and budget and summary of SMRB's history and future directions.

Address: National Institutes of Health, Building 31, 6C Room F & G, 31 Center Drive, Bethesda, MD 20894.

Meeting Format: Hybrid Meeting.

Contact Person: Tyrone Spady, Ph.D., Acting Senior Advisor to the NIH Deputy Director, Office of the Director, One Center Drive, Building 1, Room 108, Bethesda, MD 20892, (301) 496-2433, smrb@nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at <https://www.nih.gov/about-nih/visitor-information/campus-access-security> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-

issued photo ID, driver's license, or passport) and to state the purpose of their visit.

The draft meeting agenda and other information about the SMRB, including information about access to the webcast, will be available prior to the meeting at <http://smrb.od.nih.gov>.

(Catalogue of Federal Domestic Assistance Program Numbers: 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS.)

Dated: October 15, 2024.

Lauren A. Fleck,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-24125 Filed 10-17-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Bat Immunology Network Research Projects (R01 Clinical Trial Not Allowed) and Bat Immunology Network Research Resource Program (U24 Clinical Trial Not Allowed).

Date: November 25-26, 2024.

Time: 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892.

Meeting Format: Video Assisted Meeting.

Contact Person: Sandip Bhattacharyya, Ph.D., Scientific Review Officer, Scientific